Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 3/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22441786 | 1.00 | MEN1 (0.60) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL22441714 | 0.96 | MEN1 (0.57) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL22441720 | 0.96 | MEN1 (0.57) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL22441743 | 0.84 | MAPT (0.68) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL22441740 | 0.84 | MAPT (0.68) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL22441687 | 0.84 | MEN1 (0.59) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL22441633 | 0.84 | MEN1 (0.62) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL22441674 | 0.84 | MEN1 (0.59) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL22441690 | 0.84 | MEN1 (0.59) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL22441864 | 0.83 | MEN1 (0.66) | MEN1KMT2AMAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS LLC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS LLC (US) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | VHL, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 364/4885KMT2A 702/4885MAPT 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.